Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Table 3 Univariate and multivariable analyses of factors predictive of overall survival

Variables	Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	P	HR (95% CI)	P
AbiRT
Yes versus no	0.15 (0.05, 0.48)	0.001	0.17 (0.05, 0.58)	0.004
Oligometastasis
Yes versus no	0.52 (0.30, 0.93)	0.028	0.75 (0.39, 1.44)	0.387
PSA > 20 ng/mL
Yes versus no	2.16 (1.23, 3.79)	0.007	1.66 (0.93, 2.96)	0.089
Prognostic index
Interm/poor versus favorable	3.11 (1.64, 5.92)	0.001	2.71 (1.37, 5.35)	0.004
Chemo-naïve at Abi
Yes versus no	0.45 (0.25, 0.81)	0.008	0.81 (0.41, 1.61)	0.548

PSA prostate-specific antigen, Interm intermediate, Chemo-naïve chemotherapy-naïve upon abiraterone treatment, HR hazard ratio, CI confidential interval

ISSN: 1748-717X